Naproxen
Based on 7 publication(s) in Google Scholar
Naproxen is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.98%
- No. CAS: 22204-53-1
- Fòrmula: C14H14O3
- Peso molecular:230.26
-
Almacenamiento:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Naproxen
More- NPJ Digit Med. 2025 Nov 21;8(1):712. [Abstract]
- Int J Biol Macromol. 2026 Mar:352:151224. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- J Enzyme Inhib Med Chem. 2025 Dec;40(1):2501743. [Abstract]
- Biotechnol Bioeng. 2021 Dec;118(12):4687-4698. [Abstract]
- Qurina Scientific Journal. 2025.
- Chemosphere. 2019 Jun:225:378-387. [Abstract]
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Actividad biológica
|
COX-2 5.65 μM (IC50) |
COX-1 9.55 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | CC50 |
1.4 mM
Compound: Naproxen
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 30028133] |
| A549 | IC50 |
>50 μM
Compound: Naproxen
|
Cytotoxicity against human A549 cells measured after 24 to 72 hrs by MTT assay
Cytotoxicity against human A549 cells measured after 24 to 72 hrs by MTT assay
|
[PMID: 37482018] |
| BGC-823 | IC50 |
>50 μM
Compound: Naproxen
|
Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
|
[PMID: 33799070] |
| BGC-823 | IC50 |
>50 μM
Compound: Naproxen
|
Cytotoxicity against human BGC-823 cells measured after 24 to 72 hrs by MTT assay
Cytotoxicity against human BGC-823 cells measured after 24 to 72 hrs by MTT assay
|
[PMID: 37482018] |
| BXPC-3 | IC50 |
2450 μM
Compound: 1, NAP
|
Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 24273639] |
| Caco-2 | IC50 |
>50 μM
Compound: Naproxen
|
Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
|
[PMID: 33799070] |
| CHO | IC50 |
5.8 μM
Compound: Naproxen
|
TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells
TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells
|
[PMID: 10991954] |
| COS-7 | IC50 |
>1000 μM
Compound: Naproxen
|
Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 32527536] |
| DU-145 | IC50 |
>100 μM
Compound: 3; Nap
|
Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay
|
[PMID: 36257283] |
| Erythrocyte | EC50 |
756 μM
Compound: NPX
|
Antiinflammatory activity against Wistar rat erythrocytes assessed as inhibition of heat-induced hemolysis after 15 mins by membrane stabilizing activity assay
Antiinflammatory activity against Wistar rat erythrocytes assessed as inhibition of heat-induced hemolysis after 15 mins by membrane stabilizing activity assay
|
[PMID: 25863493] |
| HCT-15 | IC50 |
>1000 μM
Compound: Naproxen
|
Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 32527536] |
| HeLa | IC50 |
>50 μM
Compound: Naproxen
|
Cytotoxicity against human HeLa cells measured after 24 to 72 hrs by MTT assay
Cytotoxicity against human HeLa cells measured after 24 to 72 hrs by MTT assay
|
[PMID: 37482018] |
| HT-29 | IC50 |
2600 μM
Compound: 1, NAP
|
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 24273639] |
| HT-29 | IC50 |
>50 μM
Compound: Nap
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 26750401] |
| HT-29 | IC50 |
>50 μM
Compound: Nap
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 26750401] |
| HT-29 | IC50 |
>50 μM
Compound: Nap
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 26750401] |
| HT-29 | IC50 |
>100 μM
Compound: 3; Nap
|
Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay
|
[PMID: 36257283] |
| Jurkat | IC50 |
2550 μM
Compound: 1, NAP
|
Cytotoxicity against human Jurkat cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human Jurkat cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 24273639] |
| K562 | IC50 |
181 μM
Compound: Naproxen
|
Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 32527536] |
| MC9 | IC50 |
0.2 μM
Compound: naproxen
|
Inhibition of PGF2alpha production in mouse MC9 cells
Inhibition of PGF2alpha production in mouse MC9 cells
|
[PMID: 18498150] |
| MC9 | IC50 |
0.33 μM
Compound: naproxen
|
Inhibition of PGF2apha production in arachidonic acid-stimulated mouse MC9 cells
Inhibition of PGF2apha production in arachidonic acid-stimulated mouse MC9 cells
|
[PMID: 18498150] |
| MCF7 | IC50 |
2385 μM
Compound: 1, NAP
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 24273639] |
| MCF7 | IC50 |
>1000 μM
Compound: Naproxen
|
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 32527536] |
| MCF7 | IC50 |
>400 μM
Compound: Naproxen
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33743356] |
| MCF7 | IC50 |
>50 μM
Compound: Naproxen
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
|
[PMID: 33799070] |
| MCF7 | IC50 |
>100 μM
Compound: 3; Nap
|
Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
|
[PMID: 36257283] |
| MCF7 | IC50 |
>50 μM
Compound: Naproxen
|
Cytotoxicity against human MCF7 cells measured after 24 to 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells measured after 24 to 72 hrs by MTT assay
|
[PMID: 37482018] |
| MDA-MB-231 | IC50 |
>50 μM
Compound: Nap
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 26750401] |
| MDA-MB-231 | IC50 |
>50 μM
Compound: Nap
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 26750401] |
| MDA-MB-231 | IC50 |
>50 μM
Compound: Nap
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 26750401] |
| MDA-MB-231 | IC50 |
>400 μM
Compound: Naproxen
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33743356] |
| MDCK | CC50 |
1 mM
Compound: Naproxen
|
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by trypan blue staining based method
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by trypan blue staining based method
|
[PMID: 30028133] |
| MDCK | CC50 |
1.4 mM
Compound: Naproxen
|
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 24 to 72 hrs by MTT assay
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 24 to 72 hrs by MTT assay
|
[PMID: 30028133] |
| PANC-1 | IC50 |
>50 μM
Compound: Nap
|
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 26750401] |
| PANC-1 | IC50 |
>50 μM
Compound: Nap
|
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 26750401] |
| PANC-1 | IC50 |
>50 μM
Compound: Nap
|
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 26750401] |
| PC-3 | IC50 |
>1000 μM
Compound: Naproxen
|
Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 32527536] |
| PC-3 | IC50 |
>50 μM
Compound: Naproxen
|
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
|
[PMID: 33799070] |
| SK-LU-1 | IC50 |
>1000 μM
Compound: Naproxen
|
Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 32527536] |
| SW480 | IC50 |
>50 μM
Compound: Naproxen
|
Cytotoxicity against human SW480 cells measured after 24 to 72 hrs by MTT assay
Cytotoxicity against human SW480 cells measured after 24 to 72 hrs by MTT assay
|
[PMID: 37482018] |
| U-251 | IC50 |
>1000 μM
Compound: Naproxen
|
Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 32527536] |
| UACC-903 | IC50 |
>50 μM
Compound: Nap
|
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 26750401] |
| UACC-903 | IC50 |
>50 μM
Compound: Nap
|
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 26750401] |
| UACC-903 | IC50 |
>50 μM
Compound: Nap
|
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 26750401] |
Naproxen etemesil is a lipophilic, non-acidic, inactive prodrug of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a well known nonsteroidal anti-inflammatory drug. Naproxen is approximately equipotent inhibitor of COX-1 and COX-2 in intact cells with IC50s of 2.2 μg/mL and 1.3 μg/mL, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 22204-53-1
-
Appearance Solid
-
Peso molecular 230.26
-
Fòrmula C14H14O3
-
Color White to off-white
-
SMILES
C[C@H](C(O)=O)C1=CC2=CC=C(OC)C=C2C=C1
-
Synonyms
(S)-Naproxen
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
NPJ Digit Med
Predictive modeling & mechanistic validation of synergistic pimodivir combinations for anti-influenza therapy via PB2cap affinity boost. [Abstract]2025 Nov 21;8(1):712. PMID: 41272280 -
Int J Biol Macromol
Reticuline isomerase AKR1B1 with aldo-keto reductase activity and detoxification function from the insect Blaps rhynchopetera. [Abstract]2026 Mar:352:151224. PMID: 41791543 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
J Enzyme Inhib Med Chem
Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity. [Abstract]2025 Dec;40(1):2501743. PMID: 40371698 -
Biotechnol Bioeng
An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]2021 Dec;118(12):4687-4698. PMID: 34478150 -
Naproxen purchased from MedChemExpress. Usage Cited in: Qurina Scientific Journal. 2025.
Titration Curve of Naproxen with NaOH.
Naproxen purchased from MedChemExpress. Usage Cited in: Qurina Scientific Journal. 2025.
Electrical conductivity of Naproxen.
Naproxen purchased from MedChemExpress. Usage Cited in: Qurina Scientific Journal. 2025.
pH of Naproxen solution after UVexposure.
-
Chemosphere
Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]2019 Jun:225:378-387. PMID: 30884299
Solvente y solubilidad
DMSO : ≥ 100 mg/mL (434.29 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 75 mg/mL (325.72 mM; Need ultrasonic and warming)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 2 mg/mL (8.69 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocolo
BAEC are incubated for 30 min with Naproxen (0.1 ng/mL to 1 mg/mL). Arachidonic acid (30 μM) is then added, and the cells are incubated for a further 15 min at 37°C. The medium is then removed, and radioimmunoassay is used to measure the formation of 6-keto-PGF,a, PGE2, thromboxane B2, or PGF2a[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats[3]
To measure the analgesic effects of naproxen in a carrageenaninduced model of monoarthritis, Male Sprague–Dawley rats (n=48, 217±28 g) are randomly divided into four groups of 12 by an internally developed computer program, allowing the blind performance of the behavioral experiment. To induce hyperalgesia by inflammation, animals in groups 1B, 1C, and 1D receive a 40-μL intra-articular injection of a saline solution containing 7.5 mg/mL carrageenan in the left hind limb under isoflurane anesthesia (time=−1 h). Animals in group 1A receive no injection. After 1 h (time=0) the animals in groups 1A, 1B, 1C, and 1D receive oral doses of naproxen in saline of 0, 0, 7.5 and 30 μmol/kg, respectively. The doses and time points of measurements are selected on the basis of simulations predicting measuring a full concentration-effect relationship within the time-span of the experiment[3].
Mice[2]
Bleomycin (0.05 IU) is instilled intratracheally to C57BL/6 mice, which are then treated by micro-osmotic pump with vehicle, JNJ7777120 (40 mg/kg b.wt.), naproxen (21 mg/kg b.wt.), or a combination of both. Airway resistance to inflation, an index of lung stiffness, is assessed, and lung specimens are processed for inflammation, oxidative stress, and fibrosis markers[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (702 KB)
- English - EN (702 KB)
- Français - FR (702 KB)
- Deutsch - DE (702 KB)
- Norwegian - NO (702 KB)
- Español - ES (702 KB)
- Swedish - SV (702 KB)
- Italian - IT (702 KB)
- Korean - KR (702 KB)
- Portuguese - PT (702 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7. [Content Brief]
[2]. Rosa AC, et al. Prevention of bleomycin-induced lung inflammation and fibrosis in mice by naproxen and JNJ7777120 treatment. J Pharmacol Exp Ther. 2014 Nov;351(2):308-16. [Content Brief]
[3]. Krekels EH, et al. Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 4.3429 mL | 21.7146 mL | 43.4292 mL | 108.5729 mL |
| 5 mM | 0.8686 mL | 4.3429 mL | 8.6858 mL | 21.7146 mL | |
| 10 mM | 0.4343 mL | 2.1715 mL | 4.3429 mL | 10.8573 mL | |
| 15 mM | 0.2895 mL | 1.4476 mL | 2.8953 mL | 7.2382 mL | |
| 20 mM | 0.2171 mL | 1.0857 mL | 2.1715 mL | 5.4286 mL | |
| 25 mM | 0.1737 mL | 0.8686 mL | 1.7372 mL | 4.3429 mL | |
| 30 mM | 0.1448 mL | 0.7238 mL | 1.4476 mL | 3.6191 mL | |
| 40 mM | 0.1086 mL | 0.5429 mL | 1.0857 mL | 2.7143 mL | |
| 50 mM | 0.0869 mL | 0.4343 mL | 0.8686 mL | 2.1715 mL | |
| 60 mM | 0.0724 mL | 0.3619 mL | 0.7238 mL | 1.8095 mL | |
| 80 mM | 0.0543 mL | 0.2714 mL | 0.5429 mL | 1.3572 mL | |
| 100 mM | 0.0434 mL | 0.2171 mL | 0.4343 mL | 1.0857 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Naproxen Related Classifications
HY-15030 Related Classifications
Powered by Bioz